A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis
The Journal of Allergy and Clinical Immunology, 03/16/2012Carr W et al.
MP29–02 represents a novel therapy that demonstrated superiority to 2 first–line therapies for allergic rhinitis (AR). Patients with moderate–to–severe seasonal allergic rhinitis (SAR) achieved better control, and their symptoms were controlled earlier with MP29–02 than with recommended medications according to guidelines.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.